HPV vaccine efficacy in preventing persistent cervical HPV infection: A systematic review and meta-analysis

G. La Torre, C. de Waure, G. Chiaradia, A. Mannocci, W. Ricciardi

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Introduction: We performed a pooled analysis of randomised clinical trials (RCT) on HPV vaccine efficacy in preventing cervical persistent infection. Methods: We carried out a bibliographic search on electronic databases and we selected RCT to perform the meta-analyses. Results: We selected five studies. The first meta-analysis, including all studies, showed an important reduction of the risk of infection from HPV 16 in vaccinated cohort [RR 0.10 (95% CI: 0.07-0.15)]. The second and third meta-analyses, including only studies on bivalent and tetravalent vaccines, showed a RR of 0.13 (95% CI: 0.09-0.20) for HPV 16 infections and a RR of 0.22 (95% CI: 0.13-0.38) for HPV 18 ones. Discussion: HPV vaccine efficacy in preventing persistent infection is high but there is the need for further studies on the duration of immunization and long-term vaccine efficacy.

Original languageEnglish
Pages (from-to)8352-8358
Number of pages7
JournalVaccine
Volume25
Issue number50
DOIs
Publication statusPublished - Dec 5 2007

Fingerprint

Papillomavirus Vaccines
systematic review
meta-analysis
Meta-Analysis
Human papillomavirus 16
vaccines
randomized clinical trials
Infection
infection
Vaccines
Randomized Controlled Trials
Human papillomavirus 18
risk reduction
Risk Reduction Behavior
electronics
Immunization
immunization
Databases
duration

Keywords

  • Efficacy
  • HPV vaccine
  • Meta-analysis

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

HPV vaccine efficacy in preventing persistent cervical HPV infection : A systematic review and meta-analysis. / La Torre, G.; de Waure, C.; Chiaradia, G.; Mannocci, A.; Ricciardi, W.

In: Vaccine, Vol. 25, No. 50, 05.12.2007, p. 8352-8358.

Research output: Contribution to journalArticle

La Torre, G. ; de Waure, C. ; Chiaradia, G. ; Mannocci, A. ; Ricciardi, W. / HPV vaccine efficacy in preventing persistent cervical HPV infection : A systematic review and meta-analysis. In: Vaccine. 2007 ; Vol. 25, No. 50. pp. 8352-8358.
@article{bc2bba3fa3d84b579524f0e0985a157a,
title = "HPV vaccine efficacy in preventing persistent cervical HPV infection: A systematic review and meta-analysis",
abstract = "Introduction: We performed a pooled analysis of randomised clinical trials (RCT) on HPV vaccine efficacy in preventing cervical persistent infection. Methods: We carried out a bibliographic search on electronic databases and we selected RCT to perform the meta-analyses. Results: We selected five studies. The first meta-analysis, including all studies, showed an important reduction of the risk of infection from HPV 16 in vaccinated cohort [RR 0.10 (95{\%} CI: 0.07-0.15)]. The second and third meta-analyses, including only studies on bivalent and tetravalent vaccines, showed a RR of 0.13 (95{\%} CI: 0.09-0.20) for HPV 16 infections and a RR of 0.22 (95{\%} CI: 0.13-0.38) for HPV 18 ones. Discussion: HPV vaccine efficacy in preventing persistent infection is high but there is the need for further studies on the duration of immunization and long-term vaccine efficacy.",
keywords = "Efficacy, HPV vaccine, Meta-analysis",
author = "{La Torre}, G. and {de Waure}, C. and G. Chiaradia and A. Mannocci and W. Ricciardi",
year = "2007",
month = "12",
day = "5",
doi = "10.1016/j.vaccine.2007.09.027",
language = "English",
volume = "25",
pages = "8352--8358",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "50",

}

TY - JOUR

T1 - HPV vaccine efficacy in preventing persistent cervical HPV infection

T2 - A systematic review and meta-analysis

AU - La Torre, G.

AU - de Waure, C.

AU - Chiaradia, G.

AU - Mannocci, A.

AU - Ricciardi, W.

PY - 2007/12/5

Y1 - 2007/12/5

N2 - Introduction: We performed a pooled analysis of randomised clinical trials (RCT) on HPV vaccine efficacy in preventing cervical persistent infection. Methods: We carried out a bibliographic search on electronic databases and we selected RCT to perform the meta-analyses. Results: We selected five studies. The first meta-analysis, including all studies, showed an important reduction of the risk of infection from HPV 16 in vaccinated cohort [RR 0.10 (95% CI: 0.07-0.15)]. The second and third meta-analyses, including only studies on bivalent and tetravalent vaccines, showed a RR of 0.13 (95% CI: 0.09-0.20) for HPV 16 infections and a RR of 0.22 (95% CI: 0.13-0.38) for HPV 18 ones. Discussion: HPV vaccine efficacy in preventing persistent infection is high but there is the need for further studies on the duration of immunization and long-term vaccine efficacy.

AB - Introduction: We performed a pooled analysis of randomised clinical trials (RCT) on HPV vaccine efficacy in preventing cervical persistent infection. Methods: We carried out a bibliographic search on electronic databases and we selected RCT to perform the meta-analyses. Results: We selected five studies. The first meta-analysis, including all studies, showed an important reduction of the risk of infection from HPV 16 in vaccinated cohort [RR 0.10 (95% CI: 0.07-0.15)]. The second and third meta-analyses, including only studies on bivalent and tetravalent vaccines, showed a RR of 0.13 (95% CI: 0.09-0.20) for HPV 16 infections and a RR of 0.22 (95% CI: 0.13-0.38) for HPV 18 ones. Discussion: HPV vaccine efficacy in preventing persistent infection is high but there is the need for further studies on the duration of immunization and long-term vaccine efficacy.

KW - Efficacy

KW - HPV vaccine

KW - Meta-analysis

UR - http://www.scopus.com/inward/record.url?scp=36249026545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36249026545&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2007.09.027

DO - 10.1016/j.vaccine.2007.09.027

M3 - Article

C2 - 17996990

AN - SCOPUS:36249026545

VL - 25

SP - 8352

EP - 8358

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 50

ER -